CXCL14在子宫内膜异位症增生期内膜中的表达被引量：1

Expression of chemokine CXCL14 in the proliferative-phase endometriosis

下载PDF

导出

摘要目的:分析CXCL14在子宫内膜异位症增生期在位内膜及异位内膜中的表达情况。方法:采取Real-time PCR和免疫组织化学染色法对手术和病理确诊增生期子宫内膜异位症的18例在位内膜、24例异位内膜及20例因行卵巢囊肿、子宫肌瘤手术的增生期正常子宫内膜(术后病理除外子宫内膜异位症)进行CXCL14表达的检测。结果:1与正常内膜比较,I-IV期子宫内膜异位症在位内膜的CXCL14 m RNA和蛋白表达水平明显下调,差异有统计学意义(P<0.05);2与正常内膜比较,I-II期子宫内膜异位症在位内膜的CXCL14 m RNA和蛋白表达水平有下调,但差异无统计学意义(P>0.05);3与I-IV期子宫内膜异位症在位内膜比较,I-IV期子宫内膜异位症异位内膜的CXCL14 m RNA和蛋白表达水平明显下调,差异有统计学意义(P<0.05);与I-II期在位内膜比较,I-II期异位内膜的CXCL14 m RNA和蛋白表达水平有下调,但差异无统计学意义(P>0.05)。结论:CXCL14可能参与子宫内膜异位症的发生、发展,可能与子宫内膜异位症患者妊娠率低有关。 Objective： To analyze the expression of chemokine CXCL14 in the eutopic and ectopic endometrium of the proliferative-phase endometriosis. Methods： Real-time PCR and immunohistochemistry were ad- opted to measure and compare the CXCL14 expression in 18 cases of eutopic endometrium, 24 cases of ectopic endometrium and 20 cases of normal endometrium, which were confirmed by surgery and pathology. Results：（1） Compared to normal endometrium, the expression of chemokine CXCL 14 at mRNA and protein levels signifi- cantly declined in eutopic endometrium with stage Ill-IV, there were significant differences （P〈0.05）.（2）Com- pared to normal endometrium, the expression of chemokine CXCL14 at mRNA and protein levels declined slightly in eutopic endometrium with stage I-II, but there were no significant differences. OThe chemokine CX- CL14 at rnRNA and protein levels were significantly down-regnlated in ectopic endometrium with stage Ill-IV compared to eutopic endometrium with stage HI-IV （P〈0,05）. （4）The chemokine CXCL14 at mRNA and protein levels were slightly down-regulated in ectopic endometrium with stage I-II compared to eutopic endometrium with stage I-II. Conclusion： Our findings indicated that CXCL14 may participate in the development and pro- gression of endometriosis, which is likely associated with the low conception rates in women with endometriosis.

作者邹阮敏林刻智余霞余剑琴阮静瑶陈冠阁张文淼

机构地区温州医科大学附属第一医院妇产科温州医科大学基础医学实验中心温州医科大学附属第一医院病理科

出处《温州医科大学学报》 CAS 2016年第6期422-426,共5页 Journal of Wenzhou Medical University

基金温州市科技局科研基金资助项目(Y20140308 Y2014 0216) 浙江省自然科学青年基金资助项目(LQ15C010002)

关键词 CXCL14 子宫内膜异位症正常内膜在位内膜异位内膜 CXCL14 endometriosis normal endometrium eutopic endometrium ectopic endometrium

分类号 R711.71 [医药卫生—妇产科学]

引文网络
相关文献

参考文献28

1郎景和.子宫内膜异位症研究的新里程[J].中华妇产科杂志,2005,40(1):3-4. 被引量：277
2KAO L C, GERMEYER A, TULAC S, et al. Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation fail- ure and infertility[J]. Endocrinology, 2003, 144(7): 2870- 2881.
3KOVAL H, CHOPIAK V, KAMYSHNYI A. mRNA TLR2 and TLR4 expression in the endometrium tissue in women with endometriosis assosiated with infertility[J]. Georgian Med News, 2015(244-245): 7-11.
4YANG H, YIN J, FICARROTTA K, et al. Aberrant expres- sion and hormonal regulation of Galectin-3 in endometriosis women with infertility[J]. J Endocrinol Invest, 2016, [Epub ahead of print].
5ZHANG H, ZHANG Z, LI G, et al. Association of FCRL3 genetic polymorphisms with endometriosis-related infer- tility risk: an independent study in Han Chinese[J]. Medi- cine (Baltimore), 2015, 94(35): e 1168.
6AQHAJANOVA L, GIUDICE L C. Molecular evidence for differences in endometrium in severe versus mild endome- triosis[J]. Reprod Sci, 2010, 18(3): 229-251.
7BARTOSIK D, JACOBS S L, KELLY L J. Endometrial tis- sue inperitoneal fluid[J]. Fertil Steril, 1986, 46(5): 796-800.
8KOKS C A, GROOTHUIS P G, DUNSELMAN G A, et al. Adhension of shed menstrual tissue in an in vitro model us- ing amnion and peritoneum: a light and electron microscopic study[J]. Hum Reprod, 1999, 14(3): 816-822.
9刘海元,郎景和,刘珠凤,朱兰,冷金花,孙大为,樊庆泊.子宫内膜异位症患者在位内膜Stathmin的表达研究[J].生殖医学杂志,2013,22(9):663-667. 被引量：6
10HOU Z, SUN L, GAO L, et al. Cytokine array analysis of peritoneal fluid between women with endometriosis of different stages and those without endometriosis[J]. Bio- markers, 2009, 14(8): 604-618.

二级参考文献46

1郎景和.子宫内膜异位症研究的新里程[J].中华妇产科杂志,2005,40(1):3-4. 被引量：277
2Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects[J]. Lancet OncoL 2010, 11(7): 670-8.
3Hromas R, Bmxmeyer HE, Kim C, et al. Cloning of BRAK, a noveldivergent CXC chemokine preferentially expressed in normal versus malignant cells [J]. Biochem Biophys Res Commun, 1999, 255(3): 703-6.
4Sleeman MA, Fraser JK, Murison JG, et al. B cell- and monoeyte- activating chemokine (BMAC), a novel non-ELR alpha-chemokine [J]. Int Immunol, 2000, 12(5): 677-89.
5Frederick MJ, Henderson Y, Xu X, et al. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue[J]. Am J Pathol, 2000, 156(6): 1937-50.
6Wente MN, Mayer C, Gaida MM, et al. CXCL14 expression and potential function in pancreatic cancer [J]. Cancer Lett, 2008, 259 (2): 209-17.
7Schwarze SR, Luo J, Isaacs WB, et al. Modulation of CXCL14 (BRAK) expression in prostate cancer [J]. Prostate, 2005, 64(1): 67-74.
8Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer [ J]. Cancer Cell, 2004, 6(1): 17-32.
9Pelicano H, Lu W, Zhou Y, et al. Mitochondrial dysfunction andreactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism [J]. Cancer Res, 2009, 69(6): 2375-83.
10Ozawa S, Kato Y, Komori R, et al. BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells[J]. Biochem Biophys Res Commun, 2006, 348(2): 406-12.